The 2014 Alzheimer’s Disease Congress

Biomarker Discovery and Assay Development

Vaccine Development

Drug Discovery

With plenty of opportunity for delegates to present work and network in an informal atmosphere, with a lot of time given for discussion and debate.

www.AlzheimersDiseaseCongress2014.com

23rd-25th June 2014: LONDON, UK

This three day event will discuss aspects of Alzheimer’s Disease development and treatment in an informal academic setting. With plenty of opportunity for networking and debate, this informal international meeting will bring you up to date with current research and thinking regarding Alzheimer’s Disease.

This event has CPD accreditation and an open oral and poster session. Abstracts can be submitted on any subject related to Alzheimer’s Disease.

Talks include

• SemiAlloGeneic Vaccines for Alzheimer’s Disease, Professor Mark S. Kindy, Medical University of South Carolina, USA
• New era in AD drug design: intracellular and exosomal targets, Dr Batord Penke, Professor, University of Szeged, Department of Medical Chemistry, Hungary
• Why have we failed to cure AD?, Professor Amos Korczyn, Tel-Aviv University Medical School, Israel
• What did we learn from the first clinical trial of AB immunotherapy?, Dr Delphine Boche, Senior lecturer University of Southampton, UK
• Discovery of multtarget lead candidates to tackle the multifactorial nature of Alzheimer’s disease, Professor Andrea Cavalli, Italian Institute of Technology, Italy
• The role of herpes simplex virus type 1 in Alzheimer’s disease, Professor Ruth Frances Itzhaki, University of Manchester, UK
• Is AD A Medical Notion of Dementia Worth Keeping in Neuroscience?, Professor Fred C. C. Pong, Taipei Veterans General Hospital, Taiwan
• The biomarkers assessment in a Memory Clinic : is there any added value?, Professor Adrian Ivanoiu, Saint Luc University Hospital & Institute of Neuroscience, Catholic University of Louvain, Brussels, Belgium
• How to Prevent Dementia and Alzheimer’s, Dr Allen J. Orehek, Innovator/Physician, Dementia Prevention Center, USA
• Modulators of γ-secretase activity can facilitate the toxic side-effects and pathogenesis of Alzheimer’s disease, Dr Željko M. Svedružić, Assistant Professor, University of Rijeka, Croatia
• Regulatory T cells as new targets for immunotherapy in Alzheimer’s disease?, Dr Guillaume Dorothee, Hôpital Saint-Antoine, France
• Activities of daily living: a new approach to discovering Alzheimer therapies, Dr Robert Deacon, UK
• Cerebrospinal fluid Presenilin-1: a potential new biomarker for Alzheimer’s disease, Dr Javier Sáez-Valero, Universidad Miguel Hernández-CSIC, & Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Spain
• Investigation of novel functional and metabolic MRI biomarkers for the preclinical assessment of taupathology in AD, Dr Niall Colgan, UCL Centre for Advanced Biomedical Imaging, London, UK
• Eye movement biomarkers in Alzheimer’s disease, Dr Olivier Coubard, The Neuropsychological Laboratory, Paris, France

Additional Confirmed Speakers

• Dr Shahid Zaman, Affiliated Lecturer & Consultant Psychiatrist, Dept of Psychiatry, CIDDRG, University of Cambridge, UK
• Dr. Kailas Dashrath Sonawane, Head Department of Microbiology, Shivaji University, Maharashtra, India
• Dr Hugo Geerts, In Silico Biosciences, United State

If you would like to attend one or all of these events please
Email: leon.pein@euroscicon.com
Phone: (+44) 07507 799380
Leon can offer a bulk booking for all three events or for group registrations

Please display on a relevant notice board or email to anyone you think would like to attend